YD Bio Ltd

YDES

Market cap $799M

Taipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today rang the Opening Bell at Nasdaq MarketSite in New York to celebrate its public listing on the Nasdaq Global Market. This milestone strengthens YD Bio's capital base, elevates its global profile and accelerates the commercialization of its next-generation diagnostic and regenerative medicine platforms.

Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. (“EG BioMed”) one of the Company's licensing partners for pancreatic and breast cancer detection and with 3D Global to develop treatment for eye disorders, has been accredited by the College of American Pathologists' (CAP) Laboratory Accreditation Program for its CLIA-certified laboratory in Bothell, Washington (CLIA Certificate #50D2316600).

TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its unaudited financial results for the six months ended June 30, 2025.

Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YORK , Aug. 29, 2025 /PRNewswire/ -- YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. ("Breeze"), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols "YDES" and "YDESW," respectively.

TAIWAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. (“Breeze”), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols “YDES” and “YDESW,” respectively. The transaction was approved by Breeze shareholders at an extraordinary general meeting held on August 14, 2025.